SG11201807257VA - Ptps-based vaccines against cancer - Google Patents

Ptps-based vaccines against cancer

Info

Publication number
SG11201807257VA
SG11201807257VA SG11201807257VA SG11201807257VA SG11201807257VA SG 11201807257V A SG11201807257V A SG 11201807257VA SG 11201807257V A SG11201807257V A SG 11201807257VA SG 11201807257V A SG11201807257V A SG 11201807257VA SG 11201807257V A SG11201807257V A SG 11201807257VA
Authority
SG
Singapore
Prior art keywords
international
pct
desmoulins
villejuif
ptps
Prior art date
Application number
SG11201807257VA
Inventor
Sébastien Apcher
Robin Fahraeus
Takahiro Yamazaki
Alison Pierson
Mathilde Boulpicante
Original Assignee
Roussy Inst Gustave
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave filed Critical Roussy Inst Gustave
Publication of SG11201807257VA publication Critical patent/SG11201807257VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111 011010111 Hill 10111110H III International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ...... ... WO 2017/149118 Al 8 September 2017 (08.09.2017) WIP0 I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 39/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/055004 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, 3 March 2017 (03.03.2017) KP, MD, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, TH, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 16305243.4 3 March 2016 (03.03.2016) EP (84) Designated States (unless otherwise indicated, for every (71) Applicant: INSTITUT GUSTAVE ROUSSY [FR/FR]; kind 39 rue Camille Desmoulins, 94800 VILLEJUIF (FR). GM, of regional protection available): ARIPO (BW, GH, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors: APCHER, Sebastien; 1 rue Marius Dumont, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 95130 FRANCONVILLE (FR). FAHRAEUS, Robin; 4 TJ, me de l'Hopital Saint Louis, 75010 PARIS (FR). DK, YAMAZAKI, Takahiro; c/o GUSTAVE ROUSSY LV, SM, TRANSFERT 39 me Camille Desmoulins, 94805 VILLE- JUIF (FR). PIERSON, Alison; 151 bis Avenue de la GW, KM, ML, MR, NE, SN, TD, TG). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Republique, 94800 VILLEJUIF (FR). BOULPICANTE, Published: (74) Mathilde; 158 Boulevard Jean Mermoz Escalier B, 94550 — with CHEVILLY-LARUE (FR). — with Agent: CABINET BECKER ET ASSOCIES; 25, me international search report (Art. 21(3)) sequence listing part of description (Rule 5.2(a)) Louis le Grand, 75002 PARIS (FR). 1-1 GC 11 11 C:r 7r 11 IN 11 © (54) ei Title: PTPS-BASED VACCINES AGAINST CANCER , (57) : The present invention relates to the field of medicine. It more particularly relates to peptides, microvesicles contain - ing such peptides, compositions containing same, in particular vaccine, and methods for stimulating an immune response in a sub - .,- ject.
SG11201807257VA 2016-03-03 2017-03-03 Ptps-based vaccines against cancer SG11201807257VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305243 2016-03-03
PCT/EP2017/055004 WO2017149118A1 (en) 2016-03-03 2017-03-03 Ptps-based vaccines against cancer

Publications (1)

Publication Number Publication Date
SG11201807257VA true SG11201807257VA (en) 2018-09-27

Family

ID=55484935

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201807257VA SG11201807257VA (en) 2016-03-03 2017-03-03 Ptps-based vaccines against cancer

Country Status (10)

Country Link
US (1) US20190091307A1 (en)
EP (1) EP3423086A1 (en)
JP (1) JP2019507171A (en)
KR (1) KR102414519B1 (en)
CN (1) CN109069599A (en)
AU (1) AU2017226956A1 (en)
CA (1) CA3013685A1 (en)
IL (1) IL260988B2 (en)
SG (1) SG11201807257VA (en)
WO (1) WO2017149118A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109568570B (en) * 2019-01-14 2020-06-12 华中科技大学同济医学院附属协和医院 Anti-tumor vaccine compound, preparation method, injection and application

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69635895D1 (en) 1995-08-03 2006-05-04 Rijksuniversiteit Te Leiden Le ANTIGEN PRESENTING BUBBLES LEAVING FROM CELLS
FR2766205B1 (en) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
US7084239B1 (en) * 1997-10-08 2006-08-01 The United States Of America As Represented By The Department Of Health And Human Services Cancer peptides of NY-ESO-1/CAG-3
CN1278865A (en) * 1997-11-06 2001-01-03 罗什诊断学股份有限公司 Tumor-specific antigens, methods for their production and their use for immunization and diagnosis
CN1178956C (en) * 1998-07-31 2004-12-08 杉山治夫 Cancer antigens based on tumor suppressor gene WT1 product
FR2785543B1 (en) 1998-11-05 2003-02-28 Inst Nat Sante Rech Med MODIFIED EXOSOMES AND USES
FR2788780B1 (en) 1999-01-27 2001-03-30 Ap Cells Inc PROCESS FOR THE PREPARATION OF MEMBRANE VESICLES
AU2002331244B2 (en) 2001-08-17 2007-02-15 Exothera L.L.C. Methods and compounds for the targeting of protein to exosomes
US8333972B2 (en) * 2006-08-16 2012-12-18 Temple University Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions
US20140287022A1 (en) * 2011-04-26 2014-09-25 Molecular Express, Inc. Liposomal formulations
CN105163724A (en) * 2013-02-07 2015-12-16 葛兰素史密丝克莱恩生物有限公司 Pharmaceutical compositions comprising vesicles
JP2017101012A (en) * 2015-11-30 2017-06-08 義之 小山 Immunotherapeutic formulation

Also Published As

Publication number Publication date
CN109069599A (en) 2018-12-21
JP2019507171A (en) 2019-03-14
AU2017226956A1 (en) 2018-10-11
KR20180133405A (en) 2018-12-14
IL260988A (en) 2018-10-31
WO2017149118A1 (en) 2017-09-08
IL260988B (en) 2022-11-01
CA3013685A1 (en) 2017-09-08
EP3423086A1 (en) 2019-01-09
IL260988B2 (en) 2023-03-01
US20190091307A1 (en) 2019-03-28
KR102414519B1 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
SG11201806905UA (en) Peptides and combination of peptides for use in immunotherapy against non-small cell lung cancer and other cancers
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810149VA (en) Anti hla-g specific antibodies
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201811432WA (en) Rna for cancer therapy
SG11201808125RA (en) Methods for solid tumor treatment
SG11201807401RA (en) Therapeutic membrane vesicles
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201805120YA (en) Zika virus vaccine
SG11201805072PA (en) Nicotine powder delivery system
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201808108XA (en) Synthesis of indazoles
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201908602UA (en) Combination therapy for the treatment of solid and hematological cancers
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201807051VA (en) Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
SG11201806538WA (en) Engineered antigen presenting cells and uses thereof